|
|
|
| In honor of Dr. Donald S. Coffey - Prostate cancer biology and therapy |
| Allen C. Gaoa,James L. Mohlerb
|
a Department of Urology, University of California, Davis, Sacramento, CA, USA; Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, USA; VA Northern California Health Care System, Sacramento, CA, USA
b Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA |
|
|
|
|
Abstract This special issue of the Asian Journal of Urology (AJU) is dedicated to Donald S. Coffey, Ph.D. who passed away on Nov. 9, 2017. Dr. Coffey, professor at Johns Hopkins University, made monumental impacts on the advancement of urological research and the lives of people around him in and out of the urological research community. Dr. Coffey played an essential role in the Society for Basic Urologic Research (SBUR) as a devoted member and former president. We have collected 11 articles written by former students, trainees, fellows and colleagues of Dr. Coffey that cover a wide range of topics considered to be of prime interest to Dr. Coffey, which include the genetics, diagnosis, and treatment of advanced prostate cancer (PCa).
|
|
|
|
|
| [1] |
Isaacs WB, Xu J . Current progress and questions in germline genetics of prostate cancer. Asian J Urol 2019; 6:3-9.
doi: 10.1016/j.ajur.2018.10.001
|
| [2] |
Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL , et al. If This is True, what does it imply? How enduser antibody validation facilitates insights into biology and disease. Asian J Urol 2019; 6:10-25.
doi: 10.1016/j.ajur.2018.11.006
|
| [3] |
Zhao P, Zhu Y, Cheng L, Luo J . Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications. Asian J Urol 2019; 6:109-13.
doi: 10.1016/j.ajur.2018.09.003
|
| [4] |
Dong L, Zieren RC, Xue W, de Reijke TM, Pienta KJ . Metastatic prostate cancer remains incurable, why? Asian J Urol 2019; 6:26-41.
doi: 10.1016/j.ajur.2018.11.005
|
| [5] |
Armstrong CM, Gao AC . Current strategies for targeting the activity of androgen receptor variants. Asian J Urol 2019; 6:42-9.
doi: 10.1016/j.ajur.2018.07.003
|
| [6] |
Fiandalo MV, Gewirth DT, Mohler JL . Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer. Asian J Urol 2019; 6:50-6.
doi: 10.1016/j.ajur.2018.09.002
|
| [7] |
Etheridge T, Damodaran S, Schultz A, Richards KA, Gawdzik J, Yang B , et al. Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. Asian J Urol 2019; 6:57-64.
doi: 10.1016/j.ajur.2018.09.001
|
| [8] |
Chu GC, Chung LWK, Gururajan M, Hsieh C, Josson S, Nandana S , et al. Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics. Asian J Urol 2019; 6:65-81.
doi: 10.1016/j.ajur.2018.11.003
|
| [9] |
Dicken H, Hensley PJ, Kyprianou N . Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. Asian J Urol 2019; 6:82-90.
doi: 10.1016/j.ajur.2018.11.001
|
| [10] |
Xu L, Chen J, Liu W, Liang C, Hu H, Huang J . Targeting androgen receptor-independent pathways in therapyresistant prostate cancer. Asian J Urol 2019; 6:91-8.
doi: 10.1016/j.ajur.2018.11.002
|
| [11] |
Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT . Albuminlinked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. Asian J Urol 2019; 6:99-113.
doi: 10.1016/j.ajur.2018.11.004
|
| No related articles found! |
|
|
|
|
